Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2021
Reporting Period: Event date March 10, 2021
The Company entered into a material definitive agreement to establish an At-The-Market (ATM) equity offering program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes and Agreements
- ATM Sales Agreement: Entered into an agreement with BTIG, LLC to sell shares of common stock with an aggregate offering price of up to $45,000,000.
- Commission Structure: BTIG will receive a fixed commission rate of 3.0% of the gross proceeds from any sales.
- Sale Method: Shares may be sold through the Nasdaq Capital Market, market makers, or negotiated transactions as defined under Rule 415(a)(4).
- Obligations: The Company is not obligated to sell any shares; sales depend on market conditions and capital needs. BTIG is not obligated to purchase shares on a principal basis.
- Termination: Either party may terminate the agreement with 10 days' prior notice.
Guidance, Outlook, and Risks
Management Commentary: The Company retains sole discretion to determine the timing and amount of any sales based on market conditions and capital raising needs.
Risks and Contingencies:
- Sales are subject to customary representations, warranties, and conditions.
- The agreement is subject to limitations on the amount of stock that may be offered and sold.
- The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of a $45,000,000 offering.
- Review the Company's most recent 10-K or 10-Q to determine current cash reserves and burn rate relative to the potential $45,000,000 raise.
- Confirm the status of the shelf registration statement (File No. 333-237638) referenced in the filing.
- Monitor future filings for actual sales activity under the ATM program.